At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Market Closed 05-15 16:00:00 EDT
30.09
-0.67
-2.18%
盘后30.09
+0.000.00%
18:00 EDT
High30.90Low29.91Vol471.08K
Open30.90D1 Closing30.76Amplitude3.22%
Mkt Cap1.74BTradable Cap1.34BTotal Shares57.89M
T/O14.21MT/O Rate1.06%Tradable Shares44.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Harmony Biosciences Shareholders Approve Governance Measures at Meeting
TIPRANKS  ·  05-15 06:50
Harmony Biosciences Shareholders Approve Governance Measures at Meeting
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Maravai Lifesciences Holdings (MRVI) and Alkermes (ALKS)
TIPRANKS  ·  05-11
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Maravai Lifesciences Holdings (MRVI) and Alkermes (ALKS)
Harmony Biosciences Is Maintained at Hold by Truist Securities
Dow Jones  ·  05-09
Harmony Biosciences Is Maintained at Hold by Truist Securities
Harmony Biosciences price target raised to $29 from $25 at Truist
TIPRANKS  ·  05-08
Harmony Biosciences price target raised to $29 from $25 at Truist
Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B
TIPRANKS  ·  05-07
Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B
Stock Track | Harmony Biosciences Plunges 5.43% in Pre-Market After Q1 Earnings Miss Estimates
Stock Track  ·  05-07
Stock Track | Harmony Biosciences Plunges 5.43% in Pre-Market After Q1 Earnings Miss Estimates
GUIDANCE: (HRMY) Harmony Biosciences Expects 2026 WAKIX Net Revenue Range $1.0B - $1.04B
MT Newswires Live  ·  05-07
GUIDANCE: (HRMY) Harmony Biosciences Expects 2026 WAKIX Net Revenue Range $1.0B - $1.04B
Earnings Flash (HRMY) Harmony Biosciences Posts Q1 EPS $0.55, vs. FactSet Est of $0.69
MT Newswires Live  ·  05-07
Earnings Flash (HRMY) Harmony Biosciences Posts Q1 EPS $0.55, vs. FactSet Est of $0.69
Harmony Biosciences Q1 revenue rises less than expected
Reuters  ·  05-07
Harmony Biosciences Q1 revenue rises less than expected
Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate
Benzinga  ·  05-07
Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate
BRIEF-Harmony Biosciences Q1 Net Income USD 32.488 Million
Reuters  ·  05-07
BRIEF-Harmony Biosciences Q1 Net Income USD 32.488 Million
Harmony Biosciences: on Track to Achieve >$1 Bln in Narcolepsy Net Sales in 2026
THOMSON REUTERS  ·  05-07
Harmony Biosciences: on Track to Achieve >$1 Bln in Narcolepsy Net Sales in 2026
Harmony Biosciences Q1 Gross Profit USD 170.875 Million
THOMSON REUTERS  ·  05-07
Harmony Biosciences Q1 Gross Profit USD 170.875 Million
Harmony Biosciences Q1 Product Revenue USD 215.387 Million VS. Ibes Estimate USD 225.2 Million
THOMSON REUTERS  ·  05-07
Harmony Biosciences Q1 Product Revenue USD 215.387 Million VS. Ibes Estimate USD 225.2 Million
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
THOMSON REUTERS  ·  05-07
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 24.26%, and institutional views are predominantly bullish
Earnings Agent  ·  04-30
Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 24.26%, and institutional views are predominantly bullish
Harmony Biosciences to report first-quarter results, host conference call and webcast
Reuters  ·  04-23
Harmony Biosciences to report first-quarter results, host conference call and webcast
Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed?
Simply Wall St.  ·  04-22
Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed?
Harmony Biosciences : Oppenheimer Raises Target Price to $72 From $62
THOMSON REUTERS  ·  04-22
Harmony Biosciences : Oppenheimer Raises Target Price to $72 From $62
Harmony Biosciences to present Phase 3 ARGUS extension data for EPX-100 in Dravet syndrome
Reuters  ·  04-16
Harmony Biosciences to present Phase 3 ARGUS extension data for EPX-100 in Dravet syndrome

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--